Ar­cel­lx rais­es mega-round to put con­trol­lable CAR-T in­to the clin­ic

Last week
Financing
R&D

In­vestors throw $189M at Flag­ship star­tup's mis­sion to 'de­code' in­ter­ac­tions be­tween T cells and anti­gens

Last week
Financing

UP­DAT­ED: Sage touts first win in $3B Bio­gen pact, but safe­ty pro­file, doubts over da­ta cloud road ahead

Last week
R&D

AACR21: Eli Lil­ly blazes new trail for RET in­hibitor, gin­ning up a re­sponse in 9 sol­id tu­mor types in ear­ly da­ta

Last week
R&D
Pharma

AACR21: Bris­tol My­ers looks to build Op­di­vo's case in ear­ly can­cer with full da­ta in pre-sur­gi­cal NSCLC

Last week
R&D

AACR21: As­traZeneca un­veils next-gen PARP in­hibitor, look­ing to fol­low up on suc­cess of first-gen suc­cess sto­ry Lyn­parza

Last week
R&D

The End­points 20 un­der 40, biotech's new nor­mal, Stéphane Bancel's one re­gret, and more

Last week
Weekly

Sanofi CEO Paul Hud­son dives deep­er in­to mR­NA, buy­ing out an un­der-the-radar Fred Hutch spin­out

Last week
Deals

UP­DAT­ED: The num­bers are in, and new Ver­tex CEO Resh­ma Ke­wal­ra­mani took home half of what pre­de­ces­sor Jeff Lei­den did in his last year on the job

Last week
People

Can he pick them? A high-pro­file Wall Street an­a­lyst jumps in­to biotech as CFO of an on­col­o­gy up­start

Last week
People
Bioregnum

Trou­ble brew­ing for Proven­tion? Shares crater af­ter FDA says their teplizum­ab drug pro­file does­n't match that from for­mer own­er Eli Lil­ly

Last week
FDA+

Covid-19 roundup: BeiGene's re­pur­posed BTK in­hibitor flops in PhII tri­al; Philip­pines sus­pends As­traZeneca's vac­cine af­ter EMA draws link to blood clots

2 weeks ago
Coronavirus

Ver­sant-backed Ven­tus scores $100M round to tur­bocharge its dual-plat­form play at 'drug­ging the un­drug­gable'

2 weeks ago
Financing

Am­gen CEO Bob Brad­way takes home $20M+ pay pack­age amid bang-up year for sales

3 weeks ago
People

No­var­tis taps DNA dam­age spe­cial­ist Ar­tios in $1.3B dis­cov­ery deal to com­ple­ment grow­ing ra­di­oli­gand port­fo­lio

3 weeks ago
Deals
Discovery

UP­DAT­ED: Fi­bro­Gen shares take a beat­ing as CEO re­veals safe­ty da­ta ma­nip­u­la­tion for its block­buster con­tender rox­adu­s­tat

3 weeks ago
R&D
FDA+

As­traZeneca’s big ADC part­ner pledges to pour $13.6B in­to can­cer R&D over next 5 years — and En­her­tu looms large

3 weeks ago
Pharma

De­spite remde­sivir ap­proval and 2 big buy­outs, Gilead CEO Dan O'­Day sees pay fall 35% from 2019

3 weeks ago
People
Pharma

Big Phar­ma R&D vet­er­an with block­buster cre­den­tials re­turns to his biotech roots as Prothena's new CMO

3 weeks ago
People

With one pan­dem­ic still rag­ing, J&J bets $780M on a po­ten­tial flu ther­a­py for the next

3 weeks ago
Deals

Watch out, Bris­tol My­ers — J&J is right be­hind you; Blake By­ers leaps out from GV to do his own thing

3 weeks ago
News Briefing

Aca­dia preps for bat­tle as the FDA re­jects a po­ten­tial block­buster ap­pli­ca­tion

3 weeks ago
FDA+

UP­DAT­ED: Af­ter mil­lions of Covid vac­cine dos­es were botched, the feds hand con­trol of a trou­bled Emer­gent Bio fa­cil­i­ty to J&J

3 weeks ago
Coronavirus
Manufacturing

Al­ca­mi ap­points new CEO in Patrick Walsh, the ex­ec­u­tive who helped lead the CD­MO's pre­de­ces­sor com­pa­ny

3 weeks ago
People
Manufacturing
First page Previous page 12345 Next page Last page